Skip to main content
Log in

Follow guidance to individualize antibacterial regimens when treating infective endocarditis

  • Disease Management
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

The management of infective endocarditis requires individualized treatment and a multi-disciplinary team. Guidelines are available to help aid antibacterial decisions, taking into account the causative pathogens and patient factors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Nishimura RA, Carabello BA, Faxon DP, et al. ACC/AHA 2008 guideline update on valvular heart disease: focused update on infective endocarditis: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2008;118(8):887–96.

    Article  PubMed  Google Scholar 

  2. Mylonakis E, Calderwood SB. Infective endocarditis in adults. N Engl J Med. 2001;345(18):1318–30.

    Article  CAS  PubMed  Google Scholar 

  3. Sabe MA, Shrestha NK, Menon V. Contemporary drug treatment of infective endocarditis. Am J Cardiovasc Drugs. 2013;13(4):251–8.

    Article  CAS  PubMed  Google Scholar 

  4. Habib G, Hoen B, Tornos P, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J. 2009;30(19):2369–413.

    Article  PubMed  Google Scholar 

  5. DiNubile MJ. Short-course antibiotic therapy for right-sided endocarditis caused by Staphylococcus aureus in injection drug users. Ann Intern Med. 1994;121(11):873–6.

    Article  CAS  PubMed  Google Scholar 

  6. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18–55.

    Article  PubMed  Google Scholar 

  7. Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med. 1991;115(9):674–80.

    Article  CAS  PubMed  Google Scholar 

  8. Watkins RR, Lemonovich TL, File TM Jr. An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy. Core Evid. 2012;7:131–43.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Olaison L, Schadewitz K. Enterococcal endocarditis in Sweden, 1995–1999: can shorter therapy with aminoglycosides be used? Swedish Society of Infectious Diseases Quality Assurance Study Group for Endocarditis. Clin Infect Dis. 2002;34(2):159–66.

    Article  PubMed  Google Scholar 

  10. Fernández-Hidalgo N, Almirante B, Gavaldà J, et al. Ampicillin plus ceftriaxone is as effective as ampicillin plus gentamicin for treating Enterococcus faecalis infective endocarditis. Clin Infect Dis. 2013;56(9):1261–8.

    Article  PubMed  Google Scholar 

  11. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005;111(23):e394–434.

    Article  PubMed  Google Scholar 

  12. Rolain JM, Brouqui P, Koehler JE, et al. Recommendations for treatment of human infections caused by Bartonella species. Antimicrob Agents Chemother. 2004;48(6):1921–33.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Ellis ME, Al-Abdely H, Sandridge A, et al. Fungal endocarditis: evidence in the world literature, 1965–1995. Clin Infect Dis. 2001;32(1):50–62.

    Article  CAS  PubMed  Google Scholar 

  14. Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(5):503–35.

    Article  CAS  PubMed  Google Scholar 

  15. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007;116(15):1736–54.

    Article  PubMed  Google Scholar 

Download references

Disclosure

This article was adapted from the American Journal of Cardiovascular Drugs 2013;13(4):251–8 [3]. The preparation of these articles was not supported by any external funding.

Author information

Authors and Affiliations

Consortia

Rights and permissions

Reprints and permissions

About this article

Cite this article

Adis Medical Writers. Follow guidance to individualize antibacterial regimens when treating infective endocarditis. Drugs Ther Perspect 30, 100–104 (2014). https://doi.org/10.1007/s40267-013-0099-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40267-013-0099-8

Keywords

Navigation